MTHFR Methylation Genetic Testing: What Your Results Mean

Quick answer: MTHFR (methylenetetrahydrofolate reductase) genetic variants are present in 40-60% of the population and reduce the conversion of dietary folate to 5-methyltetrahydrofolate (5-MTHF) — the active form required for the methylation cycle. Reduced methylation capacity impairs DNA repair, neurotransmitter synthesis, homocysteine clearance (cardiovascular risk), estrogen detoxification, and cellular detoxification. The solution is not “MTHFR supplements” — it is targeted methylation support: methylfolate (5-MTHF), methylcobalamin (B12), riboflavin (B2), and betaine, with dose individualized to the variant and clinical presentation.

What Is the MTHFR Gene and Why It Matters

MTHFR (methylenetetrahydrofolate reductase) encodes the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF) — the active, bioavailable form of folate that donates a methyl group to homocysteine, converting it to methionine. Methionine is then converted to SAM (S-adenosylmethionine), the universal methyl donor used in over 200 methylation reactions throughout the body. Methylation is not a single function — it is a fundamental biochemical process controlling gene expression (epigenetic DNA methylation), neurotransmitter synthesis and degradation (dopamine, serotonin, norepinephrine), histamine clearance, estrogen metabolism, phospholipid synthesis (cell membrane integrity), glutathione production (master antioxidant), and carnitine synthesis (mitochondrial fatty acid transport). When MTHFR enzyme activity is reduced by genetic variants, every downstream methylation-dependent process is impaired — explaining the remarkably broad clinical manifestations associated with MTHFR.

The Two Primary MTHFR Variants

C677T: The Thermolabile Variant

The MTHFR C677T variant (rs1801133) produces a thermolabile enzyme with reduced activity. Heterozygous (one copy, CT genotype): 40% reduction in MTHFR enzyme activity — present in approximately 40% of the population. Homozygous (two copies, TT genotype): 70% reduction in MTHFR enzyme activity — present in approximately 10-15% of the population; higher frequency in Mediterranean and Hispanic populations (up to 20-25%). The C677T variant is most strongly associated with elevated homocysteine (cardiovascular risk), neural tube defects in pregnancies of TT mothers with inadequate folate, and elevated cancer risk in individuals with inadequate folate intake (DNA methylation impairment). The thermolabile nature of the enzyme is clinically relevant: elevated body temperature during fever or inflammation further reduces C677T enzyme activity, potentially explaining why some individuals have acute neurological or mood symptoms during fevers.

A1298C: The Under-Appreciated Variant

The MTHFR A1298C variant (rs1801131) reduces enzyme activity less severely than C677T — heterozygous A1298C produces approximately 20% reduction; homozygous CC approximately 40% reduction. A1298C is present in approximately 35% of the population as heterozygous, 10% as homozygous. Unlike C677T, A1298C is not strongly associated with elevated homocysteine on its own — its clinical implications relate more to reduced production of BH4 (tetrahydrobiopterin), a cofactor required for the synthesis of serotonin, dopamine, norepinephrine, and nitric oxide. A1298C homozygosity is associated with mood disorders, ADHD, anxiety, and fibromyalgia through BH4 insufficiency rather than homocysteine elevation. The compound heterozygous genotype (one copy of C677T + one copy of A1298C) reduces MTHFR activity by approximately 50% and represents one of the most clinically significant MTHFR presentations.

Clinical Conditions Associated with MTHFR

The clinical associations with MTHFR polymorphisms span virtually every system — reflecting the ubiquity of methylation requirements in human physiology. The most established associations: elevated homocysteine (particularly C677T TT; increases cardiovascular risk, stroke risk, and pregnancy loss risk); neural tube defects (NTDs — the most established genetic-nutritional interaction in medicine, driving universal prenatal folate recommendations); recurrent miscarriage (MTHFR reduces the folate availability required for normal placental development and DNA replication); depression and anxiety (5-MTHF is required for methylation-mediated neurotransmitter regulation; low SAM reduces serotonin and dopamine methylation; BH4 deficiency from A1298C impairs monoamine synthesis); estrogen dominance (COMT methylation of catechol estrogens requires SAM — MTHFR impairs COMT efficiency through reduced SAM production, connecting to the estrogen metabolism protocol); ADHD and autism spectrum (evidence is mixed and should not be overstated — MTHFR is a risk modifier, not a direct cause); chronic fatigue and fibromyalgia; and susceptibility to certain chemotherapy toxicities (methotrexate targets the MTHFR pathway — homozygous C677T patients have dramatically higher methotrexate toxicity).

Testing: Who Should Test for MTHFR and How

MTHFR genetic testing is available through multiple channels. Clinical laboratory testing: specialty labs (LabCorp, Quest) offer MTHFR C677T and A1298C testing, typically ordered by physicians and covered by insurance when clinically indicated (recurrent pregnancy loss, elevated homocysteine, family history of cardiovascular disease, certain chemotherapy protocols). Direct-to-consumer testing: 23andMe provides MTHFR data in its raw genetic file accessible through third-party interpretation services (Genetic Genie, StrateGene) — however, 23andMe no longer reports MTHFR directly in its health reports due to the complexity of interpretation. Comprehensive genomic testing: full methylation pathway panels (available through specialized functional medicine labs like Genova Diagnostics, Doctor’s Data) include MTHFR plus COMT, MTR, MTRR, CBS, and other methylation cycle genes — providing a more complete picture of the entire methylation network. The most clinically useful functional tests are functional rather than genetic: fasting plasma homocysteine (reflects actual methylation cycle output — more actionable than genotype alone) and RBC folate (measures intracellular folate availability).

The Methylation Cycle: Understanding the Full Network

MTHFR is one step in a larger methylation cycle that requires understanding for comprehensive treatment. The folate cycle: dietary folate (from food or folic acid supplements) → dihydrofolate (DHF) → tetrahydrofolate (THF) → 5,10-methyleneTHF → 5-MTHF (MTHFR step). The methionine cycle: 5-MTHF donates its methyl group to homocysteine (via MTR enzyme with vitamin B12 cofactor) → methionine → SAM (methyl donor) → after donating methyl group → homocysteine (recycled). Homocysteine remethylation requires MTR enzyme (with vitamin B12 and folate) or betaine-homocysteine methyltransferase (BHMT, requires betaine/TMG). Homocysteine can also be cleared via the transsulfuration pathway (CBS enzyme, requires vitamin B6) → cystathionine → cysteine → glutathione. Additional supporting nutrients: riboflavin (B2) is an essential cofactor for MTHFR enzyme activity — riboflavin deficiency is a significant but overlooked driver of reduced MTHFR function even in individuals with normal MTHFR genotype. Zinc stabilizes several methylation enzymes. Magnesium is required for DNA methyltransferase activity.

The Treatment Protocol: Supporting Methylation

5-MTHF (Methylfolate): The Foundation

The key intervention is bypassing the impaired MTHFR enzyme by supplementing the product rather than the substrate: 5-methyltetrahydrofolate (5-MTHF, also called methylfolate, L-methylfolate, or Metafolin). This provides the active folate form directly without requiring MTHFR conversion. Standard supplementation guidance by genotype: MTHFR heterozygous C677T (CT): 400-800 mcg/day 5-MTHF; MTHFR homozygous C677T (TT): 800-1,600 mcg/day 5-MTHF; compound heterozygous (C677T + A1298C): 800-1,000 mcg/day 5-MTHF; MTHFR A1298C only: 400-800 mcg/day 5-MTHF. Critical warning: some individuals — particularly those with COMT polymorphisms — experience paradoxical worsening with methylfolate (anxiety, irritability, sleep disruption, mood swings). This is called “over-methylation” or methyl trapping — a sign that the methylation cycle is being pushed too fast. If this occurs, immediately reduce or discontinue methylfolate, add niacin (500 mg as nicotinic acid acts as a methyl buffer), and reintroduce methylfolate at a much lower dose (100-200 mcg) with gradual titration. Not everyone with MTHFR tolerates aggressive methylfolate supplementation.

Methylcobalamin (Vitamin B12): The Essential Cofactor

The MTR (methionine synthase) enzyme that uses 5-MTHF to remethylate homocysteine requires vitamin B12 as an essential cofactor. Without adequate B12, even supplemented 5-MTHF cannot be utilized in the methylation cycle. Methylcobalamin (the methyl form of B12) is preferred over cyanocobalamin for methylation support — it directly participates in the methylation cycle without requiring a separate conversion step. Hydroxocobalamin is an intermediate option that can be converted to either methylcobalamin or adenosylcobalamin (the mitochondrial form) — useful in individuals with MTRR polymorphisms that impair methylcobalamin utilization. Optimal dosing for MTHFR support: 1,000-5,000 mcg/day methylcobalamin, sublingual or as lozenges (higher mucosal absorption than swallowed tablets). Serum B12 levels above 400 pg/mL and ideally above 600 pg/mL are associated with adequate functional B12 status.

Riboflavin (B2): The Forgotten MTHFR Cofactor

MTHFR is an FAD-dependent enzyme — flavin adenine dinucleotide (derived from riboflavin, vitamin B2) is the essential cofactor for MTHFR enzyme function. Riboflavin deficiency reduces MTHFR activity regardless of genotype, and riboflavin supplementation significantly improves MTHFR function in individuals with the thermolabile C677T variant. A landmark study by Horigan et al. (2010) found that riboflavin supplementation (1.6 mg/day, a modest dose) significantly reduced blood pressure in C677T homozygous individuals — an effect attributed to improved MTHFR-dependent nitric oxide metabolism. The clinical implication: before aggressive methylfolate supplementation, ensuring adequate riboflavin status is important. Riboflavin is depleted by oral contraceptive pills (significant in MTHFR patients with concurrent estrogen dominance), alcohol, and certain medications. Dose for MTHFR support: 25-50 mg/day riboflavin-5-phosphate (the active form).

Betaine (TMG): The BHMT Pathway Bypass

Betaine (trimethylglycine, TMG) provides an alternative homocysteine remethylation pathway via BHMT (betaine-homocysteine methyltransferase) that does not require 5-MTHF or vitamin B12 — making it a valuable “bypass” for individuals with severe MTHFR, MTR, or MTRR impairment. Betaine supplementation (1-3 g/day) reduces homocysteine by 10-20% in most individuals, provides three methyl groups per molecule for SAM regeneration, and is the most effective single intervention for rapidly lowering acutely elevated homocysteine. Betaine is found in beets, spinach, quinoa, and wheat germ — dietary sources can meaningfully contribute. For MTHFR patients who have difficulty tolerating methylfolate, betaine-forward protocols (2-3 g/day TMG as the primary methyl donor) can be more tolerable while still supporting methylation capacity.

Folic Acid: The MTHFR Patient’s Enemy

Folic acid (the synthetic, oxidized form of folate used in food fortification and most conventional supplements) requires conversion by DHFR (dihydrofolate reductase) and then MTHFR to become 5-MTHF. MTHFR patients process folic acid poorly — unmetabolized folic acid (UMFA) accumulates in blood, competing with and potentially blocking the transport of active methylfolate. Multiple studies have documented UMFA accumulation in MTHFR C677T TT individuals who consume high folic acid from fortified foods and conventional supplements. There is growing evidence that UMFA may impair natural killer cell function, potentially related to the folic acid fortification-associated increase in certain cancer rates observed in some epidemiological studies. The recommendation for MTHFR patients: eliminate folic acid from supplements (switch to methylfolate-containing multivitamins), reduce fortified food intake (many processed foods are enriched with folic acid), and ensure any prenatal vitamin contains 5-MTHF rather than folic acid.

MTHFR, Pregnancy, and Neural Tube Defects

The connection between MTHFR and neural tube defects (NTDs — spina bifida, anencephaly) is the most clinically established MTHFR association. Maternal MTHFR C677T homozygosity increases NTD risk 2-3× in the absence of adequate folate. The mechanism: impaired folate availability during neural tube closure (days 21-28 after conception — often before a woman knows she is pregnant) disrupts DNA methylation-dependent neural crest cell migration. The prevention strategy that has reduced NTD rates by 30-70% globally: preconception folate supplementation. For MTHFR patients planning pregnancy: 800-1,600 mcg/day 5-MTHF (not folic acid) beginning at least 3 months before conception and throughout the first trimester. Additional methylation support (methylcobalamin, betaine) is appropriate. Testing homocysteine before and during early pregnancy provides a functional measure of methylation adequacy — target below 8 μmol/L in early pregnancy.

Frequently Asked Questions

What are the symptoms of MTHFR mutation?

MTHFR polymorphisms are common enough (40-60% of the population) that calling them “mutations” is technically a misnomer — they are genetic variants. The clinical symptoms associated with significant MTHFR variants (particularly C677T TT or compound heterozygous) include: elevated homocysteine (may manifest as cardiovascular disease, blood clots, or recurrent miscarriage), depression and anxiety (reduced neurotransmitter methylation and regulation), fatigue and poor stress resilience, chemical sensitivity and difficulty detoxifying, recurrent miscarriage, birth defects in offspring, difficulty with certain medications (especially methotrexate), and elevated susceptibility to nutrient depletion from oral contraceptive pills. However, MTHFR variants are neither necessary nor sufficient to cause these conditions — they are risk modifiers that interact with nutritional status, environmental factors, and other genetic variants.

Should everyone with MTHFR take methylfolate?

Not every MTHFR carrier requires methylfolate supplementation. Whether supplementation is warranted depends on: which variant(s) and zygosity (homozygous C677T is much more impactful than heterozygous A1298C); functional methylation status as measured by homocysteine levels (if homocysteine is normal, methylation output is adequate regardless of genotype); dietary folate intake from leafy greens and legumes (adequate dietary 5-MTHF from food can compensate for moderate MTHFR impairment); and clinical symptoms potentially attributable to methylation impairment. MTHFR genotype alone is not sufficient justification for supplement use — functional methylation assessment (homocysteine, RBC folate, possibly organic acid testing showing elevated formiminoglutamic acid) provides the clinical rationale for intervention.

Can MTHFR cause depression?

MTHFR variants are associated with increased depression risk through several mechanisms: reduced SAM availability impairs the methylation-dependent regulation of serotonin, dopamine, and norepinephrine; A1298C variants reduce BH4 (tetrahydrobiopterin), which is a required cofactor for all three monoamine neurotransmitter synthesis enzymes; elevated homocysteine from C677T is directly neurotoxic via NMDA receptor activation; and impaired folate availability reduces the one-carbon metabolism that supports the methylation of phosphatidylserine (a brain phospholipid supporting neural membrane function). A 2012 meta-analysis found C677T TT homozygosity associated with 36% higher depression risk. Importantly, controlled trials of methylfolate (15 mg/day) as an adjunct to antidepressant medications have shown significant improvement in treatment-resistant depression, particularly in MTHFR carriers — supporting the mechanistic hypothesis.

What foods should MTHFR patients eat or avoid?

MTHFR patients benefit from emphasizing foods naturally rich in reduced folate forms: dark leafy greens (spinach, kale, romaine — excellent sources of 5-MTHF), legumes (lentils, chickpeas, black beans), avocado, broccoli, beets (also provide betaine), liver and organ meats (rich in B12, B2, and folate), and eggs (choline, a methyl donor). Foods and exposures to minimize: folic acid-fortified processed foods (bread, cereals, pasta — the synthetic folic acid competes with methylfolate); alcohol (depletes B2, B6, B12, and folate); and oral contraceptive pills (deplete B2, B6, and folate — a significant concern for MTHFR-positive women relying on hormonal contraception, who may need specific methylation support to compensate).

Understanding your MTHFR status and methylation capacity provides actionable insight into cardiovascular risk, neurotransmitter health, hormonal metabolism, and reproductive outcomes. Dr. Tom Biernacki offers functional medicine consultations incorporating MTHFR testing, homocysteine assessment, and individualized methylation support protocols. Call (810) 206-1402 to schedule your evaluation and develop a targeted intervention based on your genetic and functional methylation status.

MTHFR Gene Variants: What They Mean, Testing, and the Complete Methylation Protocol